Australia's most trusted
source of pharma news
Thursday, 30 April 2026
Posted 30 April 2026 PM
A deal with ASX-listed Algorae Pharmaceuticals could pave the way for ten of Zydus Lifesciences’ injectable, oral, and speciality drugs to be launched in Australia and New Zealand.
While further details on the products have not been disclosed, Algorae said the exclusive commercial and licensing agreement establishes a framework under which the companies will collaborate on the introduction of the products across hospital and community care channels.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.